New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 1, 2014
07:22 EDTINCYIncyte reports Q1 EPS (21c), consensus (18c)
Reports Q1 total revenues $89.8M, consensus $97.19M. The company said, "The increase in net loss in Q1 as compared to the same period of 2013 is primarily due to the company’s broad investment in its clinical pipeline and additional costs related to the commercialization of Jakafi in MF and preparation for the anticipated launch in PV."
News For INCY From The Last 14 Days
Check below for free stories on INCY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
07:02 EDTINCYIncyte says FDA approves supplemental labeling for Jakafi
Subscribe for More Information
July 24, 2014
06:57 EDTINCYIncyte trial miss does not impact Jakafi assumptions, says Leerink
Subscribe for More Information
July 23, 2014
16:41 EDTINCYIncyte's Ruxolitinib shows no statistical significance in primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use